Home / Cannabinoids / Novel Cannabinoids
Novel Cannabinoids
Inspired by the compounds found in cannabis, our team members have developed hundreds of novel molecules which work at the same receptor sites, in some cases with 1000x the potency. Ongoing research has shown these may have applications in next level pain relief for phantom pain, cancer related pain, treating certain forms of tumour and opiate withdrawal. These are not identical to the ‘phyto-‘ (plant) compounds, and may be even more effective in some cases.
Future Pain Relief Drugs
Our drug discovery methods involve years of trial and error with synthetic cannabinoids for theraepeutic applications producing a data set which is then provided to an AI along with what is known of the receptor site. From the AI predictions, new molecules are synthesized. We have access to a proprietary drug screening system to then be screened against banks of drug targets. Some compounds from our library have been found in indicative study projects to exhibit superior pain relief qualities to analgesics currently on the market with preferable side effect profiles. Others have been shown to possess activity against certain tumours. Some were found to ameliorate opiate cravings. These premliminary results have been promising and suggest we may have new novel medications for future use.
Medical Applications for Novel Cannabinoids
- Cannabinoids have been shows to be active in many therapeutic areas, any of which we may find a new novel medication for:
- Chronic Pain
- Phantom Limb Pain
- Cancer Related Pain
- Opiate Withdrawal
- Epilepsy
- Appetite Disorders
- Certain Tumours
- COVID
Many other areas of medicine.
What is the opportunity?
All indications were that several of our proprietary molecules could be developed into analgesic medicines and should be fast tracked for potential use in opiate withdrawal for the current fentanyl crisis.
The commericalisation pathway is the standard pharmaceutical path, we have experience in navigating the Phase 1 & 2 trials, and are in process of refining and ensuring that we have the best of the best.
BioPharm’s methods of producing generic cannabinoids using organic chemistry and propretary biosynthesis methods are not limited to phytocannabinoids, and can be adapted to produce novel pharmaceutical cannabinoids also.
